Evaluation of Colecalciferol Substitution in Dialysis Patients
Evaluation of Colecalciferol Substitution in Dialysis Patients
The purpose of this study is to determine the effect of a colecalciferol substitution in
 dialysis patients on bone metabolism and immune system
Inclusion Criteria:

 1. Serum 25-OH-Vit.D-levels < 60 ng/ml

 2. Age > 18 years

 3. dialysis treatment > 3 Months

 4. signed written informed consent

 5. Serum-Calcium-levels < 2,6 mmol/l within the last 4 weeks

 6. Serum-Phosphate-levels < 7,0 mg/dl within the last 4 weeks

 7. Ca x P-Product < 75 mg2/dl2 within the last 4 weeks

 Exclusion Criteria:

 1. Serum 25-OH-Vit.-D-levels > 60 ng/ml

 2. concommitant participation in another interventional trial

 3. psychiatric disorders preventing from valid informed consent

 4. Hyperphosphatemia (> 7,0 mg/dl) within the last 4 weeks

 5. Hypercalcemia (> 2,6 mmol/l) within the last 4 weeks

 6. Ca x P-Product > 75 mg2/dl2 within the last 4 weeks

 7. pregnancy or lactation

 8. known malignancy

 9. liver disease, defined as 2-fold upper limit of ASAT-, or ALAT-levels

 10. PTH levels < 50 pg/ml

 11. current clinically relevant infections treated with antibiotic therapy and raised
 hsCRP levels

 12. Chronic viral Infectious diseases (e.g. HIV, Hepatitis B or C)

 13. Immunosuppressant Medication

 14. known hematologic disorders, other than renal anemia

 15. age below 18 years

 16. known anaphylactic reaction against the study medication or other ingredients of the
 study drug preparation

 17. renal calculus

 18. Pseudohypoparathyroidism

 19. Medication including cardiac glycosides

 20. Sarkoidosis